Begin main content

Additional Precautions for Methicillin-Resistant Staphylococcus Aureus, Vancomycin-Resistant Enterococci and/or Extended Spectrum Beta-Lactamase-Producing Organisms: Clinical Effectiveness and Guidelines

Last updated: January 22, 2019
Project Number: RA1004-000
Product Line: Rapid Response
Research Type: Devices and Systems
Report Type: Reference List
Result type: Report

Question

  1. What is the clinical effectiveness of additional precautions for methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococci and/or extended spectrum beta-lactamase-producing organisms in patients?

Key Message

Three systematic reviews and meta-analyses, five non-randomized studies, and one evidence-based guideline were identified regarding additional precautions for Methicillin-Resistant Staphylococcus Aureus (MRSA), Vancomycin-Resistant Enterococci (VRE) and/or Extended Spectrum Beta-Lactamase(ESBL)-producing organisms.